en
svPress releases
Press release 2026-06-05
Xspray Pharma to host a conference call regarding Nilopki™
Regulatory press release 2026-06-04
Xspray Pharma Receives CRL from U.S. FDA for Nilopki™
Press release 2026-06-03
Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead
Regulatory press release 2026-05-12
Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026
Regulatory press release 2026-04-30
New number of shares and votes in Xspray Pharma after new share issue April 2026
Regulatory press release 2026-04-28
Interim Report First Quarter 2026
Regulatory press release 2026-04-23
Xspray’s rights issue oversubscribed – over-allotment issue fully utilized
Press release 2026-04-14
FDA accepts trade name Nilopki® for Xspray’s drug candidate XS003 (nilotinib)
Regulatory press release 2026-04-09
Notice of annual general meeting of Xspray Pharma AB (publ)
Regulatory press release 2026-03-31